Atara Biotherapeutics vs Fate Therapeutics
ATRA and FATE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and FATE compare
Fate Therapeutics is the larger company, worth 2.0 times as much as Atara Biotherapeutics ($161M against $79.6M).
Fate Therapeutics grew revenue faster over the last twelve months (−33.4% versus −97.4% for Atara Biotherapeutics).
Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −369% compared with −2620% at Fate Therapeutics.
Atara Biotherapeutics scores higher on the StockData Score (7 against 6 for Fate Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | FATE |
|---|---|---|
| Size and price | ||
| Market cap | $79.6M | $161M |
| Share price | $7.93 | $1.34 |
| Change, 1 year | −36.9% | 19.6% |
| Change, 5 years | −98.3% | −97.6% |
| Beta (5Y) | 1.64 | 2.40 |
| Employees | 14 | 161 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 20.1× (better) | 33.8× |
| P/B | – | 1.2× |
| FCF yield | – | −66.5% |
| Fair value | – | $1.13 |
| Margin of safety | – | −18.6% |
| Growth | ||
| Revenue growth (TTM) | −97.4% | −33.4% (better) |
| Revenue growth, 5Y average | – | −26.7% |
| Net income growth (TTM) | −162% | – |
| Profitability | ||
| Operating margin | −344% (better) | −2760% |
| Net margin | −369% (better) | −2620% |
| FCF margin | – | −2249% |
| Return on equity | – | −67.8% |
| Return on invested capital | – | −1647% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 1.72 | 4.41 (better) |
| Altman Z-score | −154.02 | −9.87 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −10.8% | – |
| Shareholder yield | −10.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 44.5% | 59.9% |
| Held by insiders | 55.5% | 25.7% |
| Insider net buying, 12 months | $2.0M (better) | −$336K |
| Short interest, % of float | 6.6% | 11.2% |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- FATE stock overview
- FATE income statement
- FATE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.